Equillium (NASDAQ:EQ) Posts Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Equillium (NASDAQ:EQ) announced its earnings results on Thursday. The company reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.06, Zacks reports. Equillium had a negative return on equity of 20.68% and a negative net margin of 10.05%. The firm had revenue of $4.39 million for the quarter.

Equillium Price Performance

EQ stock traded down $0.08 during trading on Friday, hitting $0.41. The stock had a trading volume of 214,635 shares, compared to its average volume of 360,226. The company’s 50-day moving average price is $0.76 and its two-hundred day moving average price is $0.80. Equillium has a twelve month low of $0.39 and a twelve month high of $2.45. The stock has a market capitalization of $14.53 million, a P/E ratio of -2.90 and a beta of 1.87.

Wall Street Analyst Weigh In

Separately, Leerink Partners reaffirmed a “market perform” rating and set a $1.00 price objective (down from $3.00) on shares of Equillium in a report on Friday.

Equillium Company Profile

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.